Thursday, February 14, 2013

Kaiser Report: IOM Proposes State, FDA Actions To Stop Growth Of Counterfeit Drugs


Feb 14, 2013

The Institute of Medicine Wednesday urged a series regulatory changes to help protect the public against buying fake or poorly made drugs. Medpage Today: IOM: Work Needed On Counterfeit Drug Problem
State licensing boards should restrict their licensing activities to drug wholesalers who have been vetted by the National Association of Boards of Pharmacy (NABP) as a way of strengthening the nation's drug distribution system, the Institute of Medicine (IOM) said Wednesday. Also, FDA should establish a public database to share information on suspended or revoked wholesale licenses, the body suggested as part of its long list of recommendations. "Some states require NABP accreditation of wholesalers, but unscrupulous businesses can seek out states with lower standards for their headquarters," the IOM's "Countering the Problem of Falsified and Substandard Drugs" report stated. "And, because the wholesale trade is national, weaknesses in one state's system can become vulnerabilities in another” (Pittman, 2/13).


Continue reading here

No comments: